Abstract: A method for producing shortened anionically modified cellulose fibers having an average fiber length of 1 ?m or more and 500 ?m or less, the method including cleaving sugar chains of anionically modified cellulose fibers by thermal decomposition under temperature conditions of 50° C. or higher and 230° C. or lower, wherein the average fiber length of the anionically modified cellulose fibers is 700 ?m or more and 10000 ?m or less. By the use of shortened anionically modified cellulose fibers or the like obtained by the method for production of the present invention, a dispersion containing fine cellulose fibers having a low viscosity and excellent handling property can be prepared while at a high concentration, so that the dispersion can be suitably used in various industrial applications such as daily sundries, household electric appliance parts, packaging materials for household electric appliances, automobile parts, and materials for three-dimensional modeling.

Abstract: A substrate processing method includes: (a) providing a substrate including a first region containing a first material including silicon and a second region containing a second material different from the first material; (b) etching the second region while forming a metal-containing layer on the first region, by a plasma generated from a processing gas including halogen and metal; (c) removing the metal-containing layer with a base.

Abstract: A spherical core containing an esomeprazole compound as an active ingredient and having a median particle diameter (d50) of 50 ?m or more is coated with a coat containing a controlled release layer to prepare a controlled release granule containing a controlled release granule with a median particle diameter (d50) of 350 ?m or less. The spherical core may contain the esomeprazole compound at a proportion of 50% by mass or more relative to the spherical core. The spherical core may be a spherical particle containing the esomeprazole compound as a drug. The spherical core has a median particle diameter (d50) of 50 ?m or more. The spherical core may have a sphericity of 0.6 or more. The coat may be in a multilayer free from an esomeprazole compound as an active ingredient. The controlled release layer may be an enteric coating layer. The proportion of the coat may be 80% by mass or more relative to the whole amount of the preparation.